1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
PuriBlood Medical Co.,Ltd.

PuriBlood Medical Co.,Ltd.

TTPEX:6847
68.30
TWD
-1.90
(-2.71%)
1.15BMarket Cap
PuriBlood Medical Co.,Ltd.
TPEX:6847
(Taipei Exchange)

Recent

price

68.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.29
0.36
4.41
4.64
9.58
8.73
7.71
5.74
- -
Revenue per Share
-2.09
-2.37
-0.32
-3.23
1.15
-3.59
-0.37
-2.72
- -
Basic EPS, GAAP
-2.25
-2.27
-2.25
-4.15
-2.95
1.41
-2.21
-1.94
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.29
1.85
8.37
15.08
16.23
12.62
12.22
9.77
7.62
Book Value per Share
2.42
1.12
7.74
14.45
15.16
11.76
11.54
9.26
7.19
Tangible Book Value per Share
9
9
9
12
14
14
14
14
14
Basic Weighted Avg Shares
2
3
39
55
137
125
111
82
- -
Sales/Revenue/Turnover
-723.62
-691.56
-8.53
-64.84
5.27
-40.24
-2.48
-40.61
- -
Operating Margin (%)
3
4
5
6
8
8
8
8
- -
Depreciation Expense
-18
-21
-3
-38
17
-52
-5
-39
- -
Net Income, GAAP
- -
- -
- -
- -
2.39
- -
- -
- -
- -
Effective Tax Rate (%)
-731.05
-664.29
-7.19
-69.66
12.03
-41.19
-4.85
-47.37
- -
Profit Margin (%)
16
- -
105
153
167
115
102
65
43
Working Capital
- -
29
31
27
51
44
46
37
32
LT Debt
47
27
144
216
233
181
175
140
109
Total Equity
- -
- -
- -
- -
2.63
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
6.64
- -
- -
- -
- -
Return on Capital (%)
- -
-55.71
-3.79
-22.59
7.36
-24.91
-3.01
-24.72
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
13
14
15
LT Borrowings
22
19
15
LT Finance Leases
19
18
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
1,171
1,025
1,148

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
133
124
104
Cash, Cash Equivalents & STI
81
60
40
Accounts Receivable, Net
3
30
30
Inventories
34
27
27
Total Current Liabilities
47
58
61
Payables & Accruals
- -
- -
- -
ST Debt
13
14
15
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2.46%
-20.06%
Free Cash Flow
- -
-56.47%
-12.19%
Net Income, GAAP
- -
249.97%
626.72%
Sales/Revenue/Turnover
- -
29.38%
-25.61%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
111
2025
- -
- -
82
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.37
2025
- -
- -
-2.72
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Puriblood Medical Co., Ltd. Puriblood Medical Co., Ltd. (6847.TWO) develops and sells advanced blood cell separation and filtration products utilizing proprietary Zwitterionic-bias Surface Coating Technology (ZISC technology) for medical and research applications in the healthcare sector; its core offerings include leukocyte reduction filters for red blood cells, platelets, and whole blood; real-time filtration sets for whole blood; Devin blood fractionation membrane filters; and Minipuri cell screening syringe filters such as the SFLR-P series designed for white blood cell removal from platelet-rich plasma (PRP) or platelet samples with high filtration speed, over 99.9% leukocyte reduction, over 95% red blood cell recovery, minimal volume loss, and low hemolysis even at low temperatures like 4 degrees Celsius. The company targets hospitals, blood banks, clinicians, and research institutions requiring safe transfusion and cell separation solutions for human and animal blood applications, operating primarily from its headquarters at 2F, No. 11 Gongye East 9th Road, Baoshan Township, Hsinchu City, Taiwan, where it was founded in 2016 by Dr. Yung Chang in conjunction with the R&D Center for Membrane Technology (RDCMT), holding over 36 patents supporting its membrane-based innovations. Puriblood Medical emphasizes leadership in product innovation, extensive clinician collaborations, stable quality assurance, and customized cell separation products, listing on the Taipei Exchange (TPEX) in November 2021 as a key milestone in its growth trajectory while continuing to expand its global presence in leukocyte reduction and blood purification markets through ongoing R&D and partnerships with international medical entities.